PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) ROIC %: 7.26% (As of Dec. 2025)


CAS:PRO PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
84 GF Score
Price MAD1,349.00
GF Value MAD1,327.72
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROIC %?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO 84 ROIC % is 7.26% as of Dec. 2025. GuruFocus rates CAS:PRO with a GF Score™ of 84/100 and a GF Value™ of MAD1,327.72 (Fairly Valued). The stock has 6 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was 7.26%.

As of today (2026-06-25), PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's WACC % is 10.50%. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROIC % is 7.19% (calculated using TTM income statement data). PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM earns returns that do not match up to its cost of capital. It will destroy value as it grows.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM  (CAS:PRO) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's WACC % is 10.50%. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROIC % is 7.19% (calculated using TTM income statement data). PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROIC % Related Terms


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROIC % Historical Data

* Premium members only.

The historical data trend for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROIC % Chart

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.17 24.99 12.51 9.02 7.22

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.45 8.96 8.89 6.95 7.26

CAS:PRO vs ZTS, UTHR, VTRS: ROIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROIC % distribution charts can be found below:

* The bar in red indicates where PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROIC % falls into.


CAS:PRO
84GF Score
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROIC % Calculation

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=86.367 * ( 1 - 39.1% )/( (722.994 + 734.759)/ 2 )
=52.597503/728.8765
=7.22 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1157.263 - 316.24 - ( 118.029 - max(0, 379.713 - 760.776+118.029))
=722.994

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1219.928 - 346.98 - ( 138.189 - max(0, 457.616 - 792.812+138.189))
=734.759

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=80.98 * ( 1 - 33.93% )/( (738.325 + 734.759)/ 2 )
=53.503486/736.542
=7.26 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1279.341 - 390.12 - ( 150.896 - max(0, 459.953 - 881.114+150.896))
=738.325

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1219.928 - 346.98 - ( 138.189 - max(0, 457.616 - 792.812+138.189))
=734.759

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 7.26% mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a ROIC % of 7.26% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROIC % too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ROIC % is 7.26%. The Drug Manufacturers industry median ROIC % is 4.44. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 7.26% is 63.5% above this industry median. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROIC % compare to ZTS and UTHR?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROIC % of 7.26% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.44. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 7.26% is 63.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ROIC % of 7.26% is 63.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ROIC % is 7.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,327.72, compared to a current price of MAD1,349.00 — trading 1.6% above its estimated fair value. The current ROIC % is 7.26% and 63.5% above the Drug Manufacturers industry median of 4.44. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current ROIC % is 7.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?

Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued. The current stock price of MAD1,349.00 is trading 1.6% above its estimated GF Value™ of MAD1,327.72. GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.

Key valuation signals for CAS:PRO:

  • ROIC %: 7.26%
  • GF Value™: MAD1,327.72 vs. price of MAD1,349.00 (1.6% above fair value)
  • GF Score™: 84/100 with 6 warning signs
  • Industry Position: 63.5% above the Drug Manufacturers median

No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description

Address Rue N 7, ZI du Sahel, BP 96/97, Berrechid, Had Soualem, MAR, 26400
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
84GF Score

Get the complete analysis for CAS:PRO

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MAD1,349.00
Price
MAD1,327.72
GF Value